Developing an inhaled treatment for COVID-19 and similar infections
Official title: SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections
Funded at Inhalon Biopharma, INC. · NIH-11046650 · Data updated 2026-11-12
This study is testing a new inhaled treatment for COVID-19 that uses special antibodies to help trap and remove the virus from your airways, making it easier for you to use at home and potentially keeping you out of the hospital.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Inhalon Biopharma, INC. NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project start | March 1, 2024 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,023,875 |
| NIH project number | 5R44AI177199-02 |
| Project ID | NIH-11046650 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who are at risk of severe COVID-19 or have difficulty accessing traditional treatments.
✕Less likely to help
Patients who are not infected with COVID-19 or those who have already received effective treatment may not benefit from this research.
What this research studies
This research focuses on creating an inhaled immunotherapy that targets COVID-19 and other infections by using muco-trapping antibodies. These antibodies are designed to be delivered directly to the airways through handheld nebulizers, allowing for easy self-administration at home. The approach aims to effectively trap and remove the virus from the airway mucus, potentially reducing the risk of hospitalization and retaining effectiveness against various virus variants. The treatment is designed to avoid drug-drug interactions, making it a safer option for patients.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for COVID-19 that is easy to use and minimizes hospitalization risks.
How similar studies have gone: While inhaled therapies for respiratory infections are being explored, this specific approach using muco-trapping antibodies is novel and has not been widely tested.
Where this research is happening
-
Inhalon Biopharma, INC.
Morrisville, United States Active
Researchers
- Principal investigator: Hutchins, Jeff T — Inhalon Biopharma, INC.
- Study coordinator: Hutchins, Jeff T
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.